A novel role for an old target: CD45 for breast cancer immunotherapy
Breast cancer subtypes have not shown significant response to current immunomodulatory therapies. Although most subtypes are treatable, triple negative breast cancer (TNBC), an aggressive highly metastatic cancer, comprising 10–20% of breast cancers, remains an unmet medical need. New strategies are...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/2162402X.2021.1929725 |
| _version_ | 1798034083772628992 |
|---|---|
| author | Annat Raiter Oran Zlotnik Julia Lipovetsky Shany Mugami Shira Dar Ido Lubin Eran Sharon Cyrille J. Cohen Rinat Yerushalmi |
| author_facet | Annat Raiter Oran Zlotnik Julia Lipovetsky Shany Mugami Shira Dar Ido Lubin Eran Sharon Cyrille J. Cohen Rinat Yerushalmi |
| author_sort | Annat Raiter |
| collection | DOAJ |
| description | Breast cancer subtypes have not shown significant response to current immunomodulatory therapies. Although most subtypes are treatable, triple negative breast cancer (TNBC), an aggressive highly metastatic cancer, comprising 10–20% of breast cancers, remains an unmet medical need. New strategies are needed in order to overcome flaws in the responsiveness to current TNBC therapies. Our aims were: first, to determine the efficacy of a novel immunomodulatory peptide, C24D, on TNBC and second, to elucidate the molecular mechanism by which C24D induces immune-modulating tumor killing. Using mass spectrometry analysis, we identified CD45 as the C24D binding receptor. In vitro and in vivo TNBC models were used to assess the efficacy of C24D in reversing TNBC-induced immunosuppression and in triggering immune-modulated tumor cell killing. The CD45 signal transduction pathway was evaluated by western blot and FACS analyses. We revealed that addition of PBMCs from healthy female donors to TNBC cells results in a cascade of suppressive CD45 intracellular signals. On binding to CD45’s extra-cellular domain on TNBC-suppressed leukocytes, the C24D peptide re-activates the Src family of tyrosine kinases, resulting in specific tumor immune response. In vitro, immune reactivation by C24D results in an increase of CD69+ T and CD69+ NK cells, triggering specific killing of TNBC cells. In vivo, C24D induced CD8+ and activated CD56+ tumor infiltrated cells, resulting in tumor apoptosis. Our results should renew interest in molecules targeting CD45, such as the C24D peptide, as a novel strategy for TNBC immunotherapy. |
| first_indexed | 2024-04-11T20:39:21Z |
| format | Article |
| id | doaj.art-e691ba8d4151439382e9e71a4839d3d4 |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-04-11T20:39:21Z |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-e691ba8d4151439382e9e71a4839d3d42022-12-22T04:04:17ZengTaylor & Francis GroupOncoImmunology2162-402X2021-01-0110110.1080/2162402X.2021.19297251929725A novel role for an old target: CD45 for breast cancer immunotherapyAnnat Raiter0Oran Zlotnik1Julia Lipovetsky2Shany Mugami3Shira Dar4Ido Lubin5Eran Sharon6Cyrille J. Cohen7Rinat Yerushalmi8Tel Aviv UniversityTel Aviv UniversityTel Aviv UniversityTel Aviv UniversityTel Aviv UniversityTel Aviv UniversityBeilinson Hospital, Rabin Medical CenterBar Ilan UniversityTel Aviv UniversityBreast cancer subtypes have not shown significant response to current immunomodulatory therapies. Although most subtypes are treatable, triple negative breast cancer (TNBC), an aggressive highly metastatic cancer, comprising 10–20% of breast cancers, remains an unmet medical need. New strategies are needed in order to overcome flaws in the responsiveness to current TNBC therapies. Our aims were: first, to determine the efficacy of a novel immunomodulatory peptide, C24D, on TNBC and second, to elucidate the molecular mechanism by which C24D induces immune-modulating tumor killing. Using mass spectrometry analysis, we identified CD45 as the C24D binding receptor. In vitro and in vivo TNBC models were used to assess the efficacy of C24D in reversing TNBC-induced immunosuppression and in triggering immune-modulated tumor cell killing. The CD45 signal transduction pathway was evaluated by western blot and FACS analyses. We revealed that addition of PBMCs from healthy female donors to TNBC cells results in a cascade of suppressive CD45 intracellular signals. On binding to CD45’s extra-cellular domain on TNBC-suppressed leukocytes, the C24D peptide re-activates the Src family of tyrosine kinases, resulting in specific tumor immune response. In vitro, immune reactivation by C24D results in an increase of CD69+ T and CD69+ NK cells, triggering specific killing of TNBC cells. In vivo, C24D induced CD8+ and activated CD56+ tumor infiltrated cells, resulting in tumor apoptosis. Our results should renew interest in molecules targeting CD45, such as the C24D peptide, as a novel strategy for TNBC immunotherapy.http://dx.doi.org/10.1080/2162402X.2021.1929725triple negative breast cancerperipheral blood mononuclear cellscd45specific tumor cell killing peptidesrc family of tyrosine kinases |
| spellingShingle | Annat Raiter Oran Zlotnik Julia Lipovetsky Shany Mugami Shira Dar Ido Lubin Eran Sharon Cyrille J. Cohen Rinat Yerushalmi A novel role for an old target: CD45 for breast cancer immunotherapy OncoImmunology triple negative breast cancer peripheral blood mononuclear cells cd45 specific tumor cell killing peptide src family of tyrosine kinases |
| title | A novel role for an old target: CD45 for breast cancer immunotherapy |
| title_full | A novel role for an old target: CD45 for breast cancer immunotherapy |
| title_fullStr | A novel role for an old target: CD45 for breast cancer immunotherapy |
| title_full_unstemmed | A novel role for an old target: CD45 for breast cancer immunotherapy |
| title_short | A novel role for an old target: CD45 for breast cancer immunotherapy |
| title_sort | novel role for an old target cd45 for breast cancer immunotherapy |
| topic | triple negative breast cancer peripheral blood mononuclear cells cd45 specific tumor cell killing peptide src family of tyrosine kinases |
| url | http://dx.doi.org/10.1080/2162402X.2021.1929725 |
| work_keys_str_mv | AT annatraiter anovelroleforanoldtargetcd45forbreastcancerimmunotherapy AT oranzlotnik anovelroleforanoldtargetcd45forbreastcancerimmunotherapy AT julialipovetsky anovelroleforanoldtargetcd45forbreastcancerimmunotherapy AT shanymugami anovelroleforanoldtargetcd45forbreastcancerimmunotherapy AT shiradar anovelroleforanoldtargetcd45forbreastcancerimmunotherapy AT idolubin anovelroleforanoldtargetcd45forbreastcancerimmunotherapy AT eransharon anovelroleforanoldtargetcd45forbreastcancerimmunotherapy AT cyrillejcohen anovelroleforanoldtargetcd45forbreastcancerimmunotherapy AT rinatyerushalmi anovelroleforanoldtargetcd45forbreastcancerimmunotherapy AT annatraiter novelroleforanoldtargetcd45forbreastcancerimmunotherapy AT oranzlotnik novelroleforanoldtargetcd45forbreastcancerimmunotherapy AT julialipovetsky novelroleforanoldtargetcd45forbreastcancerimmunotherapy AT shanymugami novelroleforanoldtargetcd45forbreastcancerimmunotherapy AT shiradar novelroleforanoldtargetcd45forbreastcancerimmunotherapy AT idolubin novelroleforanoldtargetcd45forbreastcancerimmunotherapy AT eransharon novelroleforanoldtargetcd45forbreastcancerimmunotherapy AT cyrillejcohen novelroleforanoldtargetcd45forbreastcancerimmunotherapy AT rinatyerushalmi novelroleforanoldtargetcd45forbreastcancerimmunotherapy |